Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurogen Acquires Phase II Wyeth Compound For Parkinson’s, RLS

This article was originally published in The Pink Sheet Daily

Executive Summary

Aplindore, a partial D2 dopamine receptor agonist, may provide dosing benefits and a better side effect profile over current treatments, firm says.

You may also be interested in...



Neurogen To Try Adipiplon In Crossover Study With Ambien

Anxiety, schizophrenia studies also part of broad effort to develop GABA-based insomnia agent.

Neurogen To Try Adipiplon In Crossover Study With Ambien

Anxiety, schizophrenia studies also part of broad effort to develop GABA-based insomnia agent.

Neurogen Will Advance Insomnia Drug Based On Positive Top-Line Phase IIb Results

Improved specificity will make NG2-73 first-line therapy of choice for the vast majority of insomnia sufferers, Neurogen R&D chief says.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel